Ledaga (Chlormethine)

Ledaga is a topical alkylating agent indicated for cutaneous T‑cell lymphomas and related skin conditions.

• Mycosis fungoides: reduces skin lesions and slows disease progression.
• Other cutaneous T‑cell lymphomas: provides local disease control and symptom relief.
• Early‑stage Sézary syndrome skin involvement: helps manage skin manifestations when systemic therapy is not required.

• Chlormethine alkylates DNA by forming cross‑links between nucleic acid strands, which interferes with DNA replication and transcription in malignant T‑cells of the skin. The resulting inhibition of cell division leads to apoptosis of the targeted cancer cells, providing localized antineoplastic activity without systemic exposure.

Adverse reactions are primarily local skin effects, but systemic toxicity can occur rarely.

Common Side Effects

• Erythema: redness at the application site.
• Pruritus: itching of treated skin.
• Burning sensation: transient heat or discomfort.
• Dryness: skin becomes flaky or scaly.
• Hyperpigmentation: darkening of the treated area.
• Contact dermatitis: mild allergic skin reaction.

Serious or Rare Side Effects

• Severe ulceration: deep skin breakdown requiring medical attention.
• Secondary bacterial or fungal infection of the lesion.
• Systemic absorption leading to bone‑marrow suppression (rare).
• Potential carcinogenic risk with long‑term use.
• Anaphylactic reaction: rare but life‑threatening hypersensitivity.
• Persistent scarring or permanent skin changes.

Before initiating therapy, clinicians should evaluate skin integrity and patient history.

• Skin assessment: ensure lesions are intact and not infected.
• Avoid broken skin: do not apply on open wounds or ulcerated areas.
• Protective gloves: wear during application to prevent accidental exposure.
• Monitor systemic toxicity: watch for signs of bone‑marrow suppression in extensive use.
• Contraindication: known hypersensitivity to chlormethine or related compounds.
• Store at room temperature: keep in the original container, protect from light and moisture.

Chlormethine may interact with other therapies that affect skin integrity or systemic toxicity.

Major Interactions (Avoid)

• Concurrent systemic chemotherapy: increased risk of bone‑marrow suppression.
• Radiotherapy to the same area: heightened skin toxicity.
• Other topical alkylating agents: additive local irritation.
• Immunosuppressants (e.g., cyclosporine): may amplify adverse skin reactions.
• High‑dose systemic retinoids: potential for severe dermatitis.

Moderate Interactions (Monitor Closely)

• Topical corticosteroids: may reduce efficacy of chlormethine.
• Phototherapy (PUVA, UVB): monitor for enhanced skin irritation.
• Moisturizers or barrier creams: assess for compatibility.
• Antibiotic ointments: watch for combined irritation.
• Systemic antihistamines: may mask early signs of allergic reaction.